RHEUMATOID ARTHRITIS: DMARD de-escalation — let the patient guide you
The DRESS study has shown that safety and efficacy were maintained for up to 3 years upon disease activity-guided dose reduction of TNF inhibitors. However, which patients are ideally suited for de-escalation remains to be investigated.
Refers to Bouman, C. A. et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study — a randomised controlled pragmatic non-inferiority strategy trial. Ann. Rheum. Dis.http://dx.doi.org/10.1136/annrheumdis-2017-211169 (2017)